Evidence concerning efficacy of antidepressants in bipolar disorder remains inconsistent and inconclusive. As the appropriate clinical use for such patients remains unclear, we characterized outpatients with bipolar disorders who were or were not treated with antidepressants. Clinical data were collected systematically from consecutive outpatients in 11 participating Argentine mood-disorder clinics in 2007-2008. Diagnoses met DSM-IV criteria, supported by structured interviews based on the MINI-500. Of 338 outpatients diagnosed with bipolar I (45.0%), II (29.3%), or not-otherwise-specified (NOS) (25.7%) disorder, 128 (37.9%) received antidepressants. Subjects given antidepressants or not did not differ significantly by presence or severity of current depression or being suicidal but were more likely to be women. Bipolar I disorder patients were three times less likely than types II or NOS to receive an antidepressant, with or without a mood-stabilizer or antimanic agent. Despite inconclusive evidence for efficacy and safety of antidepressants in various phases of bipolar disorders, 37.9% of such patients were receiving an antidepressant in 11 Argentine outpatient clinics. Antidepressant treatment was least likely with type I disorder and was independent of current depression and not associated with more use of mood-stabilizing or antimanic agents.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/hup.2253 | DOI Listing |
Child Psychiatry Hum Dev
January 2025
Department of Psychiatry and Behavioral Health, Stony Brook University, 101 Nicolls Road, Stony Brook, NY, USA.
The diagnosis of bipolar disorder (BD) in young children has been a topic of debate, in part owing to varied interpretation of manic-like symptoms. We examined how expert academic clinicians participating in the pediatric bipolar biobank varied in their interpretation and application of Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria and diagnoses. Study co-investigators reviewed 12 standardized narratives and for each marked a visual analog scale with their confidence in the presence of manic episodes and criteria.
View Article and Find Full Text PDFInt J Ment Health Nurs
February 2025
Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Knowledge is needed about end-of-life care among patients with pre-existing severe mental disorders: Schizophrenia, bipolar disorder, and depression. This study aimed to explore the experiences with end-of-life care for patients with severe mental disorders, their relatives, specialised palliative care nurses and physicians, and general practitioners. Twenty semi-structured interviews were conducted and analysed using reflexive thematic analysis, hereby six interviews with patients, three with relatives, five with general practitioners, and six with specialised palliative healthcare professionals.
View Article and Find Full Text PDFNeuropsychopharmacol Rep
March 2025
Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland.
Background: Residual fatigue is a common and debilitating symptom in patients with unipolar and bipolar depression, even after achieving partial or full remission. It significantly impacts patients' quality of life and increases the risk of relapse. This systematic review aims to evaluate the prevalence and effectiveness of therapeutic options for residual fatigue in individuals with unipolar major depressive disorder (MDD) and bipolar disorder (BD).
View Article and Find Full Text PDFAlzheimers Dement
December 2024
NeuroGenomics & Informatics Center, Washington University School of Medicine, St. Louis, MO, USA.
Background: Cerebrospinal fluid (CSF) is a valuable resource for the study and diagnosis of neurological diseases, but few studies have comprehensively characterized the genetic determinants of CSF protein levels that may contribute to the development of disease. These quantitative trait loci (QTL) have proven vital to identifying candidate genes for disease treatment and monitoring. Here, we utilize our largest-to-date CSF protein QTL atlas to prioritize potentially causal proteins for 14 neurological traits and examine the unique and overlapping disease mechanisms observed using CSF proteins.
View Article and Find Full Text PDFCannabis
December 2024
Institute for Mental Health and Policy Research, Centre for Addiction and Mental Health.
Objective: Since the federal Canadian government legalized cannabis in 2018, cannabis use in the general population has slightly increased. However, little is known about the impact of cannabis legalization on pattens of cannabis use in psychiatric populations.
Method: We studied changes in daily/almost daily and average 30-day cannabis use amongst individuals currently using cannabis who reported past 12-month experiences of specific mental health disorders and among those without past 12-month experiences of any mental health disorder before and after Canadian legalization of recreational cannabis use ( = 13,527).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!